⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 16, 2024

Supplementary Figure 2 from Clinicopathologic, genomic, and immunophenotypic landscape of ATM mutations in non-small cell lung cancer

Biagio Ricciuti Arielle Elkrief Joao V. Alessi Xinan Wang Yvonne Li Hersh Gupta Daniel M. Muldoon Arrien A. Bertram Federica Pecci Giuseppe Lamberti Alessandro Di Federico Adriana Barrichello Victor R. Vaz Malini Gandhi Elinton Lee Geoffrey I. Shapiro Hyesun Park Mizuki Nishino James Lindsay Kristen D. Felt Bijaya Sharma Andrew D. Cherniack Scott J. Rodig Daniel R. Gomez Narek Shaverdian Mehrdad Rakaee Chaitanya Bandlamudi Marc Ladanyi Pasi A. Jänne Adam J. Schoenfeld Lynette M. Sholl Mark M. Awad Michael L. Cheng

View at Publisher

Ask AI

Bookmark

Share

Abstract

Supplementary Figure 2. Proportion of samples with PD-L1 TPS ≥1%, ≥50%, ≥90% according to ATM mutation status (ATMMUT versus ATMWT).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ricciuti et al. (2024) studied this question.

synapsesocial.com/papers/68e586b5b6db643587522e4f https://doi.org/10.1158/1078-0432.27031201

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure 2 from Clinicopathologic, genomic, and immunophenotypic landscape of <i>ATM </i>mutations in non-small cell lung cancer2024
2Supplementary Figure 26 from Clinicopathologic, genomic, and immunophenotypic landscape of <i>ATM </i>mutations in non-small cell lung cancer2024
3Supplementary Figure 26 from Clinicopathologic, genomic, and immunophenotypic landscape of <i>ATM </i>mutations in non-small cell lung cancer2024
4Supplementary Figure 22. from Clinicopathologic, genomic, and immunophenotypic landscape of <i>ATM </i>mutations in non-small cell lung cancer2024
5Supplementary Figure 22. from Clinicopathologic, genomic, and immunophenotypic landscape of <i>ATM </i>mutations in non-small cell lung cancer2024

Supplementary Figure 6 from Clinicopathologic, genomic, and immunophenotypic landscape of <i>ATM </i>mutations in non-small cell lung cancer2024
Supplementary Figure 6 from Clinicopathologic, genomic, and immunophenotypic landscape of <i>ATM </i>mutations in non-small cell lung cancer2024
Supplementary Figure 24 from Clinicopathologic, genomic, and immunophenotypic landscape of <i>ATM </i>mutations in non-small cell lung cancer2024